日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

High-Titer Rheumatoid Factor is Associated with Worse Clinical Outcomes and Higher Needs for Advanced Therapies in Rheumatoid Arthritis Under Real-Life Conditions

在真实世界条件下,高滴度类风湿因子与类风湿关节炎患者更差的临床结局和更高的高级治疗需求相关。

Oliveira, Victor Davi R S; Reis, Ana Paula M G; Brenol, Claiton V; Pereira, Ivânio A; Bonfiglioli, Karina R; Pereira, Letícia R; Bértolo, Manoel B; de Fátima L C Sauma, Maria; Guimarães, Maria Fernanda B R; Louzada-Júnior, Paulo; Giorgi, Rina D N; Radominski, Sebastião C; Mota, Licia Maria H; Albuquerque, Cleandro P; Castelar-Pinheiro, Geraldo R

Erratum to "Association of food intake with sleep disorders in children and adolescents with obesity" [Sleep Med: X 4 (2022) 100053]

对“肥胖儿童和青少年食物摄入与睡眠障碍的关联”的勘误 [Sleep Med: X 4 (2022) 100053]

Zarpellon, Raquel S M; Vilela, Dra Regina M; Louzada, Fernando Mazzilli; Radominski, Dra Rosana B; Crippa, Dra Ana Chrystina de Souza

Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program

乌帕替尼在拉丁美洲类风湿性关节炎患者中的安全性:SELECT 3期临床项目的综合安全性分析

Kakehasi, Adriana Maria; Radominski, Sebastião Cezar; Baravalle, Marcos Daniel; Palazuelos, Fedra Consuelo Irazoque; Garcia-Garcia, Conrado; Arruda, Maysa Silva; Curi, Marco; Liu, John; Qiao, Meihua; Velez-Sanchez, Patricia; Vargas, Juan Ignacio

Association of food intake with sleep disorders in children and adolescents with obesity

食物摄入与肥胖儿童和青少年睡眠障碍的关系

Zarpellon, Raquel S M; Vilela, Dra Regina M; Louzada, Fernando Mazzilli; Radominski, Dra Rosana B; Crippa, Dra Ana Chrystina de Souza

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy

来自中国、巴西和韩国的类风湿性关节炎患者,对常规治疗反应不佳,使用乌帕替尼治疗。

Zeng, Xiaofeng; Zhao, Dongbao; Radominski, Sebastiao C; Keiserman, Mauro; Lee, Chang K; Meerwein, Sebastian; Enejosa, Jeffrey; Sui, Yunxia; Mohamed, Mohamed-Eslam F; Park, Won

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial

英夫利昔单抗 (IFX) 生物类似药 PF-06438179/GP1111 在类风湿性关节炎患者中长期疗效、安全性和免疫原性评估(从参考 IFX 转换或继续接受生物类似药治疗):一项随机、双盲、III 期试验的第 54-78 周数据

Cohen, Stanley B; Radominski, Sebastiao C; Kameda, Hideto; Kivitz, Alan J; Tee, Michael; Cronenberger, Carol; Zhang, Min; Hackley, Sarah; Rehman, Muhammad I; von Richter, Oliver; Alten, Rieke

Discordance between the patient's and physician's global assessment in rheumatoid arthritis: Data from the REAL study-Brazil

类风湿性关节炎患者与医生总体评估结果不一致:来自巴西 REAL 研究的数据

Guimarães, Maria Fernanda Brandão Resende; Pinto, Maria Raquel da Costa; Resende, Gustavo Gomes; Machado, Carla Jorge; Vargas-Santos, Ana Beatriz; Amorim, Rodrigo Balbino Chaves; Gomides, Ana Paula Monteiro; Albuquerque, Cleandro Pires de; Bértolo, Manoel Barros; Júnior, Paulo Louzada; Santos, Isabela Araújo; Giorgi, Rina Dalva Neubarth; Saciloto, Nathalia de Carvalho; Radominski, Sebastião Cezar; Borghi, Fernanda Maria; Bonfiglioli, Karina Rossi; Silva, Henrique Carriço da; Sauma, Maria de Fátima L da Cunha; Sauma, Marcel Lobato; Medeiros, Júlia Brito de; Pereira, Ivânio Alves; Castro, Gláucio Ricardo Werner de; Brenol, Claiton Viegas; Xavier, Ricardo Machado; Mota, Licia Maria Henrique; Castelar-Pinheiro, Geraldo da Rocha

A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis

PF-06438179/GP1111(一种英夫利昔单抗生物类似药)与参考英夫利昔单抗在中重度活动性类风湿关节炎患者中的比较研究:亚组分析

Kameda, Hideto; Uechi, Eishi; Atsumi, Tatsuya; Abud-Mendoza, Carlos; Kamei, Kazumasa; Matsumoto, Tsugumi; Ponce de Leon, Dario; Rehman, Muhammad I; Zhang, Min; Radominski, Sebastiao C

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

一项随机、双盲、III期研究比较了英夫利昔单抗生物类似药PF-06438179/GP1111与参考英夫利昔单抗:从第30周到第54周的疗效、安全性和免疫原性。

Alten, Rieke; Batko, Bogdan; Hala, Tomas; Kameda, Hideto; Radominski, Sebastiao C; Tseluyko, Vira; Babic, Goran; Cronenberger, Carol; Hackley, Sarah; Rehman, Muhammad; von Richter, Oliver; Zhang, Min; Cohen, Stanley

Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort

类风湿性关节炎患者停用合成疾病修饰药物的原因:来自大型真实世界队列的数据

Gomides, Ana Paula Monteiro; de Albuquerque, Cleandro Pires; Santos, Ana Beatriz Vargas; Amorim, Rodrigo Balbino Chaves; Bértolo, Manoel Barros; Júnior, Paulo Louzada; Santos, Isabela Araújo; Giorgi, Rina Dalva Neubarth; Sacilotto, Nathalia de Carvalho; Radominski, Sebastião Cezar; Borghi, Fernanda Maria; Guimarães, Maria Fernanda B Resende; Pinto, Maria Raquel da Costa; Resende, Gustavo Gomes; Bonfiglioli, Karina Rossi; Silva, Henrique Carriço da; Sauma, Maria de Fátima Lobato da Cunha; Sauma, Marcel Lobato; de Medeiros, Júlia Brito; Pereira, Ivânio Alves; de Castro, Gláucio Ricardo Wernwer; Brenol, Claiton Viegas; Xavier, Ricardo Machado; da Mota, Licia Maria Henrique; Pinheiro, Geraldo da Rocha Castelar